AbCellera Biologics (ABCL) has a PEG ratio of 220.97, above the sector sector average of -7.59.
Get informed when a big investor buys or sells
+ Follow220.97
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for ABCL is 220.97. That is above the sector sector average of -7.59. Investors often review this figure alongside AbCellera Biologics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, ABCL currently prints 220.97 for PEG ratio, while the sector average sits near -7.59. That is roughly 3011.2% above the sector mean. Large gaps often invite a closer look at AbCellera Biologics's growth, margins, and balance sheet.
A PEG ratio of 220.97 for AbCellera Biologics is not 'good' or 'bad' on its own. Compare it with the peer average (-7.59) and with ABCL's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ABCL's PEG ratio (220.97), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.